IDWeek 2018

LEAP 2 Study Shows Oral Lefamulin Is Safe and Effective in Treatment of Adults with Community-Acquired Bacterial Pneumonia
IDWeek 2018
Evaluation of lefamulin, a novel oral antimicrobial, in patients with community-acquired bacterial pneumonia demonstrated noninferiority for both the US Food and Drug Administration and European Medicines Agency efficacy end points versus oral moxifloxacin. Read More ›
Systematic Review and Network Meta-Analysis of Randomized Trials of Antibiotic Therapy for Community-Acquired Pneumonia
IDWeek 2018
In patients with community-acquired pneumonia, a regimen that includes a fluoroquinolone (and possibly a macrolide) may reduce mortality compared with beta-lactams (with or without a beta-lactamase inhibitor) and cephalosporins alone. Read More ›
The AMMO Study: Antimicrobial Management in Extracorporeal Membrane Oxygenation
IDWeek 2018
A protocol to guide rational antibiotic therapy in patients receiving extracorporeal membrane oxygenation can lead to a reduction in the use of specific antibiotics, but paradoxically, may increase overall antibiotic use. Read More ›

Page 3 of 3

© Amplity Health. All Rights Reserved. Privacy Policy